Ratings Celldex Therapeutics, Inc.

Equities

CLDX

US15117B2025

Real-time Estimate Cboe BZX Other stock markets 09:51:47 2024-06-10 am EDT			5-day change	1st Jan Change
34.49 ^USD	-2.24%		+3.29%	-12.83%

Jun. 05	Celldex Therapeutics Insider Sold Shares Worth $1,579,353, According to a Recent SEC Filing	MT
Jun. 05	Celldex Therapeutics Insider Sold Shares Worth $1,964,088, According to a Recent SEC Filing	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

Over the last twelve months, the sales forecast has been frequently revised upwards.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
CELLDEX THERAPEUTICS, INC.	-12.83%	2.33B	C-
MODERNA, INC.	+47.14%	57.87B	B-
LONZA GROUP AG	+40.57%	40.25B	A
IQVIA HOLDINGS INC.	-6.53%	39.94B	B
CELLTRION, INC.	-5.16%	28.54B	C
ICON PUBLIC LIMITED COMPANY	+10.70%	26.4B	B-
ALNYLAM PHARMACEUTICALS, INC.	-20.21%	19.33B	B
MEDPACE HOLDINGS, INC.	+30.79%	12.4B	C+
BIO-TECHNE CORPORATION	-0.41%	12.23B	B+
UNITED THERAPEUTICS CORPORATION	+22.83%	12.2B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes